Understanding Age-Related Macular Degeneration

Age-related macular degeneration (AMD) represents the leading cause of vision loss among adults over 50 in developed countries. This progressive condition damages the macula, the central portion of the retina responsible for sharp, detailed vision. When the macula deteriorates, individuals experience blurriness, distortion, or darkness in their central vision, making activities like reading, driving, and recognizing faces increasingly difficult.

AMD exists in two primary forms: dry (atrophic) and wet (neovascular). Dry AMD accounts for approximately 85-90% of cases and typically progresses more slowly, characterized by the accumulation of drusen (yellow deposits) under the retina. Wet AMD, while less common, can cause more rapid and severe vision loss due to abnormal blood vessels growing beneath the retina and leaking fluid or blood. Understanding these distinctions is crucial as treatment approaches vary significantly between types.

Anti-VEGF Therapy: The Current Standard of Care

Anti-vascular endothelial growth factor (anti-VEGF) medications have revolutionized wet AMD treatment over the past two decades. These injectable drugs work by inhibiting the protein that stimulates abnormal blood vessel growth and leakage in the retina. Regular injections can slow disease progression and even improve vision in some cases.

The treatment protocol typically involves an initial series of monthly injections followed by a personalized maintenance schedule. While these injections represent a significant advancement, they require ongoing treatment to maintain effectiveness. The procedure itself is performed in-office by retina specialists using local anesthesia. Most patients report minimal discomfort during the quick procedure, though the need for regular visits can be burdensome for some individuals.

Extended-Release Delivery Systems

One of the most promising recent breakthroughs addresses the burden of frequent anti-VEGF injections. Extended-release delivery systems now offer longer-lasting treatment effects. Genentech developed Susvimo (formerly Port Delivery System), an implantable reservoir that slowly releases medication into the eye, requiring refills approximately every six months instead of monthly injections.

Similarly, Regeneron Pharmaceuticals has introduced high-dose formulations of their anti-VEGF medication that extend the duration between treatments. These innovations significantly reduce the treatment burden on patients while maintaining therapeutic effectiveness. For individuals with mobility challenges or those living far from specialized care centers, these extended-release options represent a meaningful quality-of-life improvement while managing their condition.

Emerging Therapies for Dry AMD

Until recently, no FDA-approved treatments existed for the more common dry form of AMD. However, Apellis Pharmaceuticals received approval for Syfovre (pegcetacoplan injection), the first treatment specifically for geographic atrophy, an advanced form of dry AMD. This complement inhibitor targets an overactive part of the immune system that contributes to retinal cell death.

Other promising approaches in clinical trials include neuroprotective agents that preserve retinal cells, visual cycle modulators that reduce toxic byproduct accumulation, and stem cell therapies aimed at replacing damaged retinal cells. IVERIC bio has developed Zimura (avacincaptad pegol), another complement inhibitor showing positive results in clinical trials. These developments represent significant hope for patients with a condition previously considered untreatable.

Gene Therapy and Future Directions

Gene therapy represents the frontier of AMD treatment research, with the potential to provide long-term solutions with minimal interventions. Several approaches are under investigation, including delivering genes that produce anti-VEGF proteins continuously within the eye and correcting genetic mutations associated with AMD risk.

REGENXBIO is developing RGX-314, a one-time gene therapy treatment designed to enable retinal cells to produce their own anti-VEGF protein. Adverum Biotechnologies is working on ADVM-022, another gene therapy candidate administered through a single intravitreal injection. While still experimental, these approaches could potentially eliminate the need for ongoing injections while providing sustained therapeutic effects, fundamentally changing how we manage AMD in the future.

Conclusion

The landscape of macular degeneration treatment has evolved dramatically, with options now available for both wet and dry forms of the disease. From extended-release delivery systems to the first approved treatments for dry AMD and promising gene therapies on the horizon, patients have more reason for optimism than ever before. While a definitive cure remains elusive, these innovations are preserving vision and improving quality of life for millions affected by this condition.

If you're experiencing vision changes, early intervention remains crucial. Regular eye exams can detect AMD before symptoms become noticeable, and prompt treatment typically yields better outcomes. As research continues to advance, the future holds even greater promise for those affected by macular degeneration.

Citations

This content was written by AI and reviewed by a human for quality and compliance.